Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 374 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Child, Only Clear all
Completed Not applicable Interventional Results available

A Single-Session Intervention for Families on Waitlists for Child Anxiety Treatment

NCT05841680
View directory record Official record
Conditions
Anxiety Disorders
Interventions
SSI Module
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
7 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283
View directory record Official record
Conditions
Chronic Kidney Disease, Proteinuria, Children
Interventions
Finerenone (Kerendia, BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
1 Year to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 4 Interventional Results available

Propofol in Emergence Agitation

NCT00535613
View directory record Official record
Conditions
Emergence Agitation
Interventions
Propofol
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
12 Months to 6 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Jul 22, 2026, 10:41 AM EDT
Withdrawn Phase 1 Interventional

Randomized Trial Comparing Single vs. Maintenance Fecal Microbiota Transplant for Refractory Crohn's Disease in Children

NCT03747718
View directory record Official record
Conditions
Crohn Disease
Interventions
Fecal Microbiota Transplantation, Placebo
Biological · Other
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Jul 22, 2026, 10:41 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

NCT02948127
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV LID cp ΔM2-2 Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
3
States / cities
Baltimore, Maryland • Laurel, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems

NCT06957756
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
BI 1584862
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Chandler, Arizona • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections

NCT01893346
View directory record Official record
Conditions
Systemic Infections
Interventions
CAZ-AVI
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment

NCT04587622
View directory record Official record
Conditions
Hepatic Failure
Interventions
Icenticaftor
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

NCT01852266
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV cps2 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Laurel, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Not applicable Interventional

CT Scan Using IV Contrast Alone for Pediatric Appendicitis

NCT00716703
View directory record Official record
Conditions
Appendicitis, Child, Contrast Media
Interventions
CT Scan using IV contrast alone
Other
Lead sponsor
University of Rochester
Other
Eligibility
3 Years to 18 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2008 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Phase 1 Interventional

A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia

NCT06810583
View directory record Official record
Conditions
Leukemia, Acute Myeloid Leukemia, Lymphoblastic Leukemia in Children
Interventions
Dalbavancin, Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician)
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 25 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.

NCT05329623
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
JDQ443
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting No phase listed Observational

Rapid-Response EEG in Children With Suspected Status Epilepticus

NCT06564662
View directory record Official record
Conditions
Status Epilepticus, Coma
Interventions
Rapid Response EEG
Device
Lead sponsor
Children's Hospital at Montefiore
Other
Eligibility
2 Years to 18 Years
Enrollment
60 participants
Timeline
2021 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Phase 3 Interventional

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

NCT04715646
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
1 Month and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
2
States / cities
Hawthorne, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Immune Responses to Gluten

NCT05209568
View directory record Official record
Conditions
Celiac Disease, Malabsorption Syndromes, Digestive System Disease, Intestinal Disease, Gastrointestinal Diseases, Gluten Sensitivity, Celiac Disease in Children
Interventions
Gluten Powder
Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 101 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

NCT04923126
View directory record Official record
Conditions
Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma
Interventions
Mirdametinib
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 24 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Results available

Pediatric Pharmacokinetic (PK) Study of EXE844 Otic Suspension in Otitis Media at the Time of Tympanostomy Tube Insertion (OMTT)

NCT02539654
View directory record Official record
Conditions
Otitis Media With Effusion in Children, Otitis Media Recurrent
Interventions
EXE844 Sterile Otic Suspension, 0.3%, Tympanostomy Tube Insertion
Drug · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
6 Months to 12 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Jul 22, 2026, 10:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Acceptability and Feasibility of a Single-Session Online Parent-Focused Intervention Targeting Child Body Image Development

NCT07179068
View directory record Official record
Conditions
Eating Disorders, Body Image Disturbance, Weight Bias
Interventions
Child Body Image Development Workshop
Behavioral
Lead sponsor
University at Albany
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 2 Interventional Results available

A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy

NCT01643408
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
asparaginase Erwinia chrysanthemi
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Los Angeles, California • Orange County, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

NCT02932410
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan, Standard-of-care
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
1 Month to 17 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Not applicable Interventional

Day and Night Closed-loop in Young People With Type 1 Diabetes

NCT02925299
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases
Interventions
FlorenceM (US) and FlorenceX (UK), Insulin pump therapy
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
6 Years to 18 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Palo Alto, California • Aurora, Colorado • Hartford, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fruit and Vegetable Intake in Preschoolers

NCT05730530
View directory record Official record
Conditions
Children, Only, Nutrition, Healthy
Interventions
Nutrition education curriculum
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
3 Years to 5 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer

NCT00002611
View directory record Official record
Conditions
Kidney Cancer
Interventions
dactinomycin, filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
0 Years to 15 Years
Enrollment
3,031 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2003
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Jul 22, 2026, 10:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Buffered Local Anesthetic

NCT05757648
View directory record Official record
Conditions
Dental Pain
Interventions
Non-buffered Anesthetic, Buffered Anesthetic, Onset
Drug · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
2 Years to 6 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Jul 22, 2026, 10:41 AM EDT